Research ExplorerPublicationsUse of monoclonal antibody therapy for nosocomial SARS-CoV-2...

Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

Standard

Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. / Koehler, Johanna; Ritzer, Barbara; Weidlich, Simon; Gebhardt, Friedemann; Kirchhoff, Chlodwig; Gempt, Jens; Querbach, Christiane; Hoffmann, Dieter; Haller, Bernhard; Schmid, Roland M; Schneider, Jochen; Spinner, Christoph D; Iakoubov, Roman.

In: INFECTION, Vol. 49, No. 6, 12.2021, p. 1313-1318.

Research output: SCORING: Contribution to journal › Short publication › Research › peer-review

Harvard

Koehler, J, Ritzer, B, Weidlich, S, Gebhardt, F, Kirchhoff, C, Gempt, J, Querbach, C, Hoffmann, D, Haller, B, Schmid, RM, Schneider, J, Spinner, CD & Iakoubov, R 2021, 'Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany', INFECTION, vol. 49, no. 6, pp. 1313-1318. https://doi.org/10.1007/s15010-021-01657-y

APA

Koehler, J., Ritzer, B., Weidlich, S., Gebhardt, F., Kirchhoff, C., Gempt, J., Querbach, C., Hoffmann, D., Haller, B., Schmid, R. M., Schneider, J., Spinner, C. D., & Iakoubov, R. (2021). Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. INFECTION, 49(6), 1313-1318. https://doi.org/10.1007/s15010-021-01657-y

Vancouver

Koehler J, Ritzer B, Weidlich S, Gebhardt F, Kirchhoff C, Gempt J et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. INFECTION. 2021 Dec;49(6):1313-1318. https://doi.org/10.1007/s15010-021-01657-y

Bibtex

@article{58d1b460fcb34e4f806fa5a20abc373d,
title = "Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany",
abstract = "Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.",
keywords = "Antibodies, Monoclonal/therapeutic use, COVID-19, Cross Infection/drug therapy, Cross-Sectional Studies, Germany, Humans, Retrospective Studies, SARS-CoV-2, Tertiary Care Centers",
author = "Johanna Koehler and Barbara Ritzer and Simon Weidlich and Friedemann Gebhardt and Chlodwig Kirchhoff and Jens Gempt and Christiane Querbach and Dieter Hoffmann and Bernhard Haller and Schmid, {Roland M} and Jochen Schneider and Spinner, {Christoph D} and Roman Iakoubov",
note = "{\textcopyright} 2021. The Author(s).",
year = "2021",
month = dec,
doi = "10.1007/s15010-021-01657-y",
language = "English",
volume = "49",
pages = "1313--1318",
journal = "INFECTION",
issn = "0300-8126",
publisher = "Urban und Vogel",
number = "6",

}

RIS

TY - JOUR

T1 - Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany

AU - Koehler, Johanna

AU - Ritzer, Barbara

AU - Weidlich, Simon

AU - Gebhardt, Friedemann

AU - Kirchhoff, Chlodwig

AU - Gempt, Jens

AU - Querbach, Christiane

AU - Hoffmann, Dieter

AU - Haller, Bernhard

AU - Schmid, Roland M

AU - Schneider, Jochen

AU - Spinner, Christoph D

AU - Iakoubov, Roman

N1 - © 2021. The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.

AB - Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.

KW - Antibodies, Monoclonal/therapeutic use

KW - COVID-19

KW - Cross Infection/drug therapy

KW - Cross-Sectional Studies

KW - Germany

KW - Humans

KW - Retrospective Studies

KW - SARS-CoV-2

KW - Tertiary Care Centers

U2 - 10.1007/s15010-021-01657-y

DO - 10.1007/s15010-021-01657-y

M3 - Short publication

C2 - 34244967

VL - 49

SP - 1313

EP - 1318

JO - INFECTION

JF - INFECTION

SN - 0300-8126

IS - 6

ER -